Patent · US Active

Antibodies against human angiopoietin 2

US9340609B2 · kind B2 · utility

2Cited by

8References

5Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Ulrich Brinkmann · Weilheim, DE
Remko Albert Griep · Slemmestad, NO
Klaus Kaluza · Bad Heilbrunn, DE
Anita Kavlie · Oslo, NO
Christian Klein · Iffeldorf, DE
Joerg Thomas Regula · Munich, DE
Werner Scheuer · Penzberg, DE

Key dates

Filing date	Dec 4, 2012
Grant date	May 17, 2016
Priority date	—
Expiry date	Jul 17, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: The present invention also relates to a method for preventing metastasis in a patient suffering from primary cancer comprising administering, to a patient in need of such preventative treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.